02 Sep 2020 Rewind Therapeutics appoints biopharmaceutical industry veteran Kees Been as Non-Executive Director Member news
02 Sep 2020 BioLizard expands services in Switzerland with appointment of Per Rigler as Business Development Manager Member news
01 Sep 2020 Oxurion NV reports first patient dosed in Phase 2 study evaluating THR-149 for treatment of Diabetic Macular Edema (DME) Member news
27 Aug 2020 Newton Biocapital I invests in J-Pharma Co., Ltd. in Japan focusing on drug development targeting L-type Amino Acid Transporter 1 (LAT1) for cancer and autoimmune diseases Member news
More info? Ellen Telleir Communications Project Manager linkedin.com/in/ellentelleir/ ellen.telleir@biovia.be Contact us